ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tinengotinib

Also written as “TT-00420”, “TT-00420 (tinengotinib)” and “tinengotinib 10 mg QD plus darolutamide”.

Its studies are mostly in Cholangiocarcinoma · Prostatic Neoplasms · Breast Neoplasms · Carcinoma, Hepatocellular · Triple Negative Breast Neoplasms, led by 2 companies.

Drug pageTinengotinib: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 29, 202311 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TransThera Sciences (Nanjing)105 open or runningphase 3since Jun 29, 2023Aug 21, 2018Dec 2026phase 3 · NCT05948475
Akesoits history only11 open or runningphase 2since Jun 26, 2025Jun 26, 2025May 10, 2027phase 2 · NCT07052253

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of TransThera Sciences (Nanjing) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 21, 2018First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT03654547 · 48 enrolled · United States, China
  2. Jan 6, 2021Phase 1 study in HealthyNCT04705922 · 24 enrolled · United States
  3. Feb 2, 2021Phase 2 study in CholangiocarcinomaNCT04742959 · 203 enrolled · United States
  4. May 27, 2021Phase 2 study in CholangiocarcinomaNCT04919642 · 55 enrolled · United States
  5. Jan 25, 2022Named tinengotinibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TT-00420
  6. Jan 26, 2022Phase 2 study in CholangiocarcinomaNCT05253053 · 84 enrolled · China
  7. Jun 29, 2023Phase 3 study in CholangiocarcinomaNCT05948475 · 200 enrolled · United States, Austria, Belgium and more
  8. Sep 5, 2023Phase 2 study in Cholangiocarcinoma MetastaticNCT06057571 · 50 enrolled · China
  9. Dec 26, 2025Phase 3 study in CholangiocarcinomaNCT07328919 · 138 planned · China
  10. Mar 19, 2026Phase 2 study in Breast NeoplasmsNCT07498478 · 94 planned · China
  11. Oct 3, 2026Phase 2 study in Prostatic NeoplasmsNCT07871110 · 182 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in CholangiocarcinomaNCT05948475
  2. Jun 30, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07498478
  3. Dec 31, 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT07871110
  4. Dec 31, 2029Primary completion: phase 3 study in CholangiocarcinomaNCT07328919

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 TransThera Sciences (Nanjing) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07871110Prostatic Neoplasms · China2RecruitingDec 31, 2028182
NCT07498478Breast Neoplasms · China2RecruitingJun 30, 202794
NCT07328919Cholangiocarcinoma · China3Not yet recruitingDec 31, 2029138
NCT06057571Cholangiocarcinoma Metastatic · China2Active, not recruitingJul 27, 202550
NCT05948475Cholangiocarcinoma · United States, Austria, Belgium and more3Active, not recruitingDec 2026200
NCT05253053Cholangiocarcinoma · China2CompletedAug 31, 202484
NCT04919642Cholangiocarcinoma · United States2CompletedFeb 28, 202455
NCT04742959Cholangiocarcinoma · United States2CompletedFeb 20, 2024203
NCT04705922Healthy · United States1CompletedMar 7, 202124
NCT03654547Triple Negative Breast Neoplasms · United States, China1CompletedJan 31, 202348

How it is read

Names in the registry

  • “TT-00420”, 4 entries
  • “TT-00420 (tinengotinib)”, 3 entries
  • “tinengotinib 10 mg QD plus darolutamide”, 1 entry
  • “tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide”, 1 entry
  • “tinengotinib 10 mg QD plus enzalutamide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.